Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX)’s traded shares stood at 83.31 million during the latest session, with the company’s beta value hitting 1.82. At the last check today, the stock’s price was $0.44, to imply an increase of 43.99% or $0.13 in intraday trading. The QNRX share’s 52-week high remains $6.18, putting it -1304.55% down since that peak but still an impressive 36.36% since price per share fell to its 52-week low of $0.28.

Analysts have given a consensus recommendation of Buy for Quoin Pharmaceuticals Ltd ADR (QNRX), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give QNRX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy.

Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX) trade information

After registering a 43.99% upside in the latest session, Quoin Pharmaceuticals Ltd ADR (QNRX) has traded red over the past five days. The 5-day price performance for the stock is 33.17%, and 38.50% over 30 days. With these gigs, the year-to-date price performance is -31.89%.

An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -194.79% for the past 5-year period. While 2025 is set for a 78.42% return in earnings, projections for the next 5 years are at 82.69% annually.

QNRX Dividends

Quoin Pharmaceuticals Ltd ADR has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Going by data provided on Apr 30, 2024 , Fidelity NASDAQ Composite Index Fund holds roughly 95.0 shares. This is just over 0.00% of the total shares, with a market valuation of $37.0